Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05027594 · ClinicalTrials.gov registry record · Phase 1
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Nerviano Medical Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT05027594 is a Phase 1 study that was terminated before completion, run by Nerviano Medical Sciences. The registered enrollment target is 5 participants.
The verdict
NCT05027594, a Phase 1 study, was terminated before completion, sponsored by Nerviano Medical Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable.
Interventions
- DRUG NMS-03597812
- DRUG NMS-03597812 + dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-09-09 |
| Est. Completion | 2024-01-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05027594
The ClinicalTrials.gov registry entry for NCT05027594 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nerviano Medical Sciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NMS-03597812 is the first listed.
NCT05027594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05027594 about?
NCT05027594 is a clinical study titled "Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma". This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard treatment options that are expected to provide mean...
What is the current status of trial NCT05027594?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2022-09-09. Estimated completion is 2024-01-08.
What interventions are being tested in trial NCT05027594?
The interventions under investigation include: NMS-03597812 (DRUG), NMS-03597812 + dexamethasone (DRUG).
Who is sponsoring clinical trial NCT05027594?
This trial is sponsored by Nerviano Medical Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.